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Eltoprazine counteracts L-DOPA-induced
dyskinesias in Parkinson’s disease: a
dose-finding study
Per Svenningsson,1 Carl Rosenblad,2 Karolina af Edholm Arvidsson,1 Klas Wictorin,2
Charlotte Keywood,3 Bavani Shankar,4 David A. Lowe,4 Anders Björklund5 and
Håkan Widner2
See Bezard and Carta for a scientific commentary on this article (doi:10.1093/brain/awu407).
In advanced stages of Parkinson’s disease, serotonergic terminals take up L-DOPA and convert it to dopamine. Abnormally
released dopamine may participate in the development of L-DOPA-induced dyskinesias. Simultaneous activation of 5-HT1A and
5-HT1B receptors effectively blocks L-DOPA-induced dyskinesias in animal models of dopamine depletion, justifying a clinical
study with eltoprazine, a 5-HT1A/B receptor agonist, against L-DOPA-induced dyskinesias in patients with Parkinson’s disease.
A double-blind, randomized, placebo-controlled and dose-finding phase I/IIa study was conducted. Single oral treatment with
placebo or eltoprazine, at 2.5, 5 and 7.5 mg, was tested in combination with a suprathreshold dose of L-DOPA (Sinemet) in
22 patients with Parkinson’s disease (16 male/six female; 66.6  8.8 years old) with L-DOPA-induced dyskinesias. A Wilcoxon
Signed Ranked Test was used to compare each eltoprazine dose level to paired randomized placebo on the prespecified primary
efficacy variables; area under the curve scores on Clinical Dyskinesia Rating Scale for 3 h post-dose and maximum change of
Unified Parkinson’s Disease Rating Scale part III for 3 h post-dose. Secondary objectives included effects on maximum Clinical
Dyskinesia Rating Scale score, area under the curve of Rush Dyskinesia Rating Scale score for 3 h post-dose, mood parameters
measured by Hospital Anxiety Depression Scale and Montgomery Asberg Depression Rating Scale along with the pharmaco-
kinetics, safety and tolerability profile of eltoprazine. A mixed model repeated measures was used for post hoc analyses of the
area under the curve and peak Clinical Dyskinesia Rating Scale scores. It was found that serum concentrations of eltoprazine
increased in a dose-proportional manner. Following levodopa challenge, 5 mg eltoprazine caused a significant reduction of L-
DOPA-induced dyskinesias on area under the curves of Clinical Dyskinesia Rating Scale [–1.02(1.49); P = 0.004] and Rush
Dyskinesia Rating Scale [–0.15(0.23); P = 0.003]; and maximum Clinical Dyskinesia Rating Scale score [–1.14(1.59); P = 0.005].
The post hoc analysis confirmed these results and also showed an antidyskinetic effect of 7.5 mg eltoprazine. Unified
Parkinson’s Disease Rating Scale part III scores did not differ between the placebo and eltoprazine treatments. The most
frequent adverse effects after eltoprazine were nausea and dizziness. It can be concluded that a single dose, oral treatment
with eltoprazine has beneficial antidyskinetic effects without altering normal motor responses to L-DOPA. All doses of elto-
prazine were well tolerated, with no major adverse effects. Eltoprazine has a favourable risk-benefit and pharmacokinetic profile
in patients with Parkinson’s disease. The data support further clinical studies with chronic oral eltoprazine to treat L-DOPA-
induced-dyskinesias.
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Introduction
Parkinson’s disease is characterized by bradykinesia, rigid-
ity, tremor and gait disturbances largely due to the pro-
gressive loss of midbrain dopaminergic neurons
innervating the striatum (Lees et al., 2009). Dopamine
replacement strategies are effective for many motor symp-
toms and throughout the disease course essentially all pa-
tients with Parkinson’s disease will receive treatment with
L-DOPA. In a healthy individual, L-DOPA is converted by
amino acid decarboxylase to dopamine within dopamin-
ergic neurons and is released via normal synaptic and non-
synaptic mechanisms. In Parkinson’s disease, conversion
sites for L-DOPA to dopamine diminish progressively. A
series of abnormal compensatory cellular and receptor
complex alterations develop to counteract the dopamine
deficiency. These alterations, together with L-DOPA treat-
ment, result in wearing-off of medication effects and de-
velopment of abnormally regulated movements, known as
L-DOPA-induced dyskinesias (LIDs) (Obeso et al., 2000;
Lees et al., 2009).
Several cellular and molecular mechanisms have been pro-
posed to explain the development and onset of LIDs in
Parkinson’s disease (Obeso et al., 2000; Cenci et al., 2011;
Huot et al., 2013). One possibility is that in advanced stage
of dopaminergic cell loss, the remaining serotonergic neu-
rons in the basal ganglia complex can specifically take up
L-DOPA and convert it to dopamine (Ng et al., 1970, 1971;
Hollister et al., 1979). In contrast to the normal situation,
release of dopamine occurs in this setting when the seroto-
nergic neurons are activated and dopamine functions as a
false transmitter. This abnormally released dopamine stimu-
lates postsynaptic dopamine receptors in an uncontrolled
manner (Tanaka et al., 1999; Carta et al., 2007). In particu-
lar, uncontrolled stimulation of supersensitized dopamine D1
receptors in the direct striatonigral pathway are thought to
mediate LIDs (Obeso et al., 2000; Cenci et al., 2011; Huot
et al., 2013). Accordingly, LIDs in rats and monkeys can be
reduced by pharmacological autoinhibition or lesioning of
serotonin neurons (Bibbiani et al., 2001; Carta et al.,
2007; Bezard et al., 2013). Serotonin release is regulated
by somatodendritic 5-HT1A receptors and nerve terminal
5-HT1B receptors. In animal models of Parkinson’s disease,
5-HT1A and 5-HT1B receptor agonists act synergistically
and can completely eliminate LIDs (Carta et al., 2007). Of
particular interest are recent animal data using eltoprazine, a
selective partial agonist at the 5-HT1A and 5-HT1B recep-
tors. Acute administration of eltoprazine reduced LIDs at a
low dose (0.3 mg/kg) in 6-hydroxydopamine (6-OHDA)
lesioned rats treated with L-DOPA (Bezard et al., 2013). In
chronic studies, eltoprazine provided protection against the
development of LIDs and suppressed already developed LIDs
at doses of 0.3 mg/kg and 0.6 mg/kg. In a non-human pri-
mate model of LIDs [1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) monkeys treated with L-DOPA], an acute
dose of eltoprazine at 0.75 mg/kg showed suppression of
dyskinesias (Bezard et al., 2013).
Oral or intravenous eltoprazine has previously been admin-
istered to4600 male and female subjects in single and multiple
dose safety and efficacy studies (Raghoebar et al., 1990;
Verhoeven et al., 1992; Kohen, 1993; Tiihonen et al., 1993;
de Koning et al., 1994; Wigal and Doung, 2011). Doses, ran-
ging between 0.25 and 30 mg, were given to 300 healthy
subjects (Raghoebar et al., 1990; Wigal and Duong, 2011)
and4300 patients suffering from mental handicap and aggres-
sion (Verhoeven et al., 1992; Kohen et al., 1993; Tiihonen et al.,
1993; de Koning et al., 1994) or attention deficit hyperactivity
disorder (ADHD; ClinicalTrials.gov Identifier:
NCT01266174). Overall the drug has been safe and
well-tolerated. Eltoprazine has uncomplicated absorption,
distribution, metabolism, and excretion parameters. The
dose-limiting adverse events with single doses were nausea
and somnolence/sedation, which were present at 5 mg, but
reduced upon repeated dosing. Eltoprazine was originally de-
veloped to treat aggressive behaviour in psychiatric disorders
(Raghoebar et al., 1990; Kohen, 1993; Tiihonen et al., 1993;
de Koning et al., 1994) and was recently tested as a procognitive
agent in a clinical trial in patients with ADHD
(ClinicalTrials.gov Identifier: NCT01266174).
The positive effects of eltoprazine against LIDs in animal
models and its beneficial safety profile in humans led us to
evaluate eltoprazine as a potential novel therapy against
LIDs in patients with Parkinson’s disease. Placebo has a
strong effect on LIDs (Goetz et al., 2008), so it is critical
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to perform placebo-controlled trials when evaluating
treatment effects on LIDs. We therefore undertook a
phase I/IIA, double-blind, randomized, placebo-controlled,
dose finding study with single oral eltoprazine treatment in
an L-DOPA challenge-dose setting.
Materials and methods
Patients
The study population was planned to consist of 24 Parkinson’s
disease patients with LIDs, recruited at Karolinska Hospital
and Skåne University Hospital in Sweden. The demographics
of the intention to treat group (n = 22) are presented in
Table 1. Among these patients, 12 (equally divided over the
two sites) were selected to be part of a pharmacokinetic popu-
lation and subjected to blood sampling for the assessment of
serum concentrations of eltoprazine.
Ethics
In this double-blind, placebo-controlled, phase I/IIa first time in
PD patients study, male and female patients with a diagnosis of
idiopathic moderate Parkinson’s disease and LIDs were
included. Exclusion criteria were atypical or secondary parkin-
sonism, signs of dementia or depression, a history of structural
brain disease or ongoing treatment with amantadine and/or
serotonergic compounds. Further details of inclusion and exclu-
sion criteria are available in the Supplementary material.
As this study was the first exposure of eltoprazine to patients
with Parkinson’s disease, it was conducted as a single-dose,
dose-finding study. Dose selection for this trial was based on
previous clinical experience with eltoprazine demonstrating
‘neuroactivity’ (Raghoebar et al., 1990; Verhoeven et al.,
1992; Kohen et al., 1993; Tiihonen et al., 1993; de Koning
et al., 1994; Wigal and Duong, 2011; ClinicalTrials.gov
Identifier: NCT01266174) as well as conventional scaling cal-
culations based on pharmacokinetic exposures in various animal
model studies demonstrating neuroactivity. Doses ranging be-
tween 0.25 and 30 mg have been administered to healthy sub-
jects or patients in the aforementioned clinical trials. The doses
(2.5, 5 and 7.5 mg) administered in this study were lower than
those given to most of the healthy volunteers (Raghoebar et al.,
1990; Wigal and Duong, 2011) and patients in other popula-
tions (Verhoeven et al., 1992; Kohen et al., 1993; Tiihonen
et al., 1993; de Koning et al., 1994; ClinicalTrials.gov
Identifier: NCT01266174). It was therefore believed that the
benefit that could be obtained from this study would outweigh
any risks. The study was approved by The Swedish Medical
Product Agency, the local Ethics Committee, and performed
in accordance with the Declaration of Helsinki and
International Conference on Harmonization Good Clinical
Practice guidelines. All patients provided informed written con-
sent before enrolment. The study was registered with the Eudra
CT number 2009-015928-28 and conducted between 15
December 2010 and 11 January 2012.
Randomization and masking
The investigational medicinal product was eltoprazine hydro-
chloride 2.5 mg capsules or matching placebo, labelled at the
manufacturer. Patients were randomized to one of four sequence
groups to receive three single doses of oral eltoprazine (2.5, 5 and
7.5 mg). An additional study treatment of ‘randomized placebo’
was administered in one of Visits 3 to 6 and ‘run-in placebo’ was
administered at Visit 2. For details on randomization, see the
Supplementary material.
Procedures
As outlined in Fig. 1, patients first made a screening visit
(Visit 1). Included patients then made five dosing visits and
were exposed to placebo (twice) and all three eltoprazine (2.5,
5 and 7.5 mg) dosages, before making a final end-of-study visit
(Visit 7). The investigator obtained a patient’s written informed
consent form before any study-related activity began. After sign-
ing the informed consent form, patients were screened for in-
clusion/exclusion criteria and safety assessments (for further
details see Supplementary material). All concomitant medica-
tions were to be registered in the case report form.
At screening, symptoms of parkinsonism, depression, anxiety
and vital signs were assessed as indicated in the study flow
chart (Supplementary Table 1). Electrocardiography and
blood draws for haematology and clinical chemistry were
also performed, as well as screening for significant LIDs con-
ducted by a suprathreshold challenge dose of L-DOPA
Table 1 Demographics of study participants.
Variable Intention to treat
population
(n = 22)
Age (years) 66.6 (8.8)
Male/female 16 (72.7%)/6 (27.3%)
Height (cm) 172.6 (10.1)
Weight (kg) 69.9 (12.0)
Caucasian 22 (100%)
Disease duration (years) 11.6 (3.1)
LIDs (years) 3.41 (1.40)









Peak-dose dyskinesias 22 (100%)
L-DOPA 22 (100%)
DA agonist 17 (77%)
MAOB inhibitor 9 (41%)
COMT inhibitor 15 (68%)
LED (mg) 1191 (495)
The measures are taken from the intention to treat study population on the day of
screening. For categorical variables; n (%) is presented. For continuous variables; mean
(standard deviation). LID severity is indicated by results from questions 32–34 of
UPDRS-IV, indicating duration, disability and painfulness of LIDs. L-DOPA equivalent
(LED) was calculated according to Tomlinson et al. (2010).
DA = dopamine.
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(calculated as 150% of his/her regular dose up to a maximum
of 250 mg). L-DOPA was given as Sinemet (L-DOPA com-
bined with carbidopa in a fixed ratio of 4:1). The patients
fasted 2 h prior to dosing and allowed to eat 1 h post-
dosing. Patients were observed for a period of 3 h after dosing.
Following the initial screening procedure (Visit 1), patients
who met inclusion/exclusion criteria were scheduled to visit the
clinic six times (during a period of 32 days after enrolment),
where five visits were dosing visits and and one visit was a
follow-up visit (final visit/early termination visit). Planned
study visits and all study activities that were performed at
the visits are described by the study flow chart
(Supplementary Table 1). All study visits should have occurred
within 5-day window of the time points, except for Visit 2,
which could have occurred within 30 days after screening.
During each of the dosing visits (Visits 3 to 6), patients
received suprathreshold dosage of L-DOPA. In addition, they
received either placebo or one of three doses (2.5, 5, or 7.5 mg)
of eltoprazine. The patients were rated with the Unified
Parkinson’s Disease Rating Scale part III (UPDRS-III),
Clinical Dyskinesia Rating Scale (CDRS) (Hagell et al.,
1999) and Rush Dyskinesia Rating Scale (RDRS) (Goetz
et al., 1994) and observed (video filmed) just before dosing
with L-DOPA and study medication (i.e. t = 0) and at 30-min
intervals up to 180 min after the challenge test of L-DOPA and
study medication (5 min of filming each time). The order of
film sequences was blinded to the assessors. Separate code lists
were generated for each site (and kept at the respective site).
Each film sequence file was copied and renamed with an allo-
cated code before distribution to the independent assessors.
Each sequence was then rated by two independent, blinded
raters, who had never met the patients. Scorings of the
videos were made for UPDRS-III (except for rigidity which
was scored on site during the visit), CDRS and RDRS.
A 2-day diary with three symptom lines—off, on (normal),
on with dyskinesia (Reimer et al., 2004)—were filled out by
the patients between the screening and enrolment visits, and in
between Visits 2 to 6 (1 day before dosing and one day after
dosing) to evaluate any changes in perceived dyskinesia by the
patients.
Assessment of psychiatric symptoms with the Hospital
Anxiety and Depression Scale (HADS) was performed at
each visit of the study. All adverse events were recorded in
the case report form.
Twelve patients (equally divided over the two sites) were
also subjected to additional blood sampling for the measure-
ment of serum concentrations of eltoprazine for pharmacoki-
netic analysis. Eltoprazine serum concentrations were assessed
pre-dose and 1, 2 and 4 h post-dose at all dosing occasions.
Serum was analysed for eltoprazine by a validated liquid chro-
matography/mass spectroscopy/mass spectroscopy assay
(Biopharmaceutical Research Inc).
The study site was visited periodically by a monitor con-
tracted by the sponsor. The monitor had direct access to
case report forms, clinical records, original laboratory reports
and other source data. All information recorded in case report
forms was verified against source data. All discovered devi-
ations from the procedures that could have affected observa-
tional data were recorded.
Outcome measures
The prespecified primary objective of this study was to deter-
mine the effective dose of eltoprazine on the suppression of
LIDs in Parkinson’s disease patients treated with L-DOPA
while maintaining the normal treatment effect of L-DOPA
using the following efficacy measures: (i) dyskinesia ratings
calculated as CDRS AUC0-3 (area under curve 3 h post-dose)
after L-DOPA and study medication intake; and (ii) the highest
observed change in UPDRS III score up to 3 h after study
medication was used to detect any deterioration of the
normal treatment effect of L-DOPA. The highest observed
change being defined as the difference between the maximum
UPDRS III score 3 h post-dosing and the UPDRS III prior to
any study medication.
The prespecified secondary objectives of this study were:
(i) Number, frequency and severity of any adverse event recorded
during the five test episodes that differ between eltoprazine and
placebo;
(ii) Dyskinesia ratings calculated as RDRS AUC0-3 after L-DOPA and
study medication intake;
(iii) Dyskinesia ratings scored as the maximum score for CDRS rat-
ings over 3 h after L-DOPA and study medication intake;
(iv) Changes in the diary data between baseline and placebo at any of
the three study medication dosages;
Figure 1 Trial profile.
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(v) Change of the HADS score after study medication compared with
placebo; and
(vi) Development of depression over the course of the study period
determined by the Montgomery Åsberg Depression Rating Scale
and clinical judgement.
Statistical analyses
The number of patients recruited to the study was based on a
previous antidyskinetic study (Memdy04; Wictorin, Widner
et al. unpublished data), in which memantine was given to
Parkinson’s disease patients with LIDs. Significant antidyski-
netic effects of memantine were found in a crossover study of
two consecutive 4-week treatment periods with 17 patients in
the per protocol population and 19 patients in the intention to
treat population. Based on comparative animal studies (Bezard
et al., 2013), the effect size of eltoprazine is in the same range
as memantine. The target number for inclusion was therefore
set to 24. For the single L-DOPA challenge dosages, no similar
data exist, but all recruited patients were included.
Unless otherwise stated, data are presented as mean  stand-
ard deviation (SD). The statistical analysis planned a priori
was the Wilcoxon Signed-Rank test with paired comparisons
between each dosing of eltoprazine and the randomized pla-
cebo. Both intention to treat and per protocol populations
were analysed.
A post hoc analysis, using a SAS v9.3 and mixed model,
repeated measures, of the CDRS AUC0-3 and peak dose
CDRS (defined as the measurement 90 min post-dosing with
L-DOPA) was performed, to obtain measures of within- and
between-subject variability and understand better the magni-
tude of effect of eltoprazine. A post hoc of CDRS at each time
point post L-DOPA dosing was performed, to better under-
stand the dose response over the 3 h post-dosing. The post
hoc analyses also allowed for the inclusion of baseline data
collected at Visits 1 and 2. All available data on the intention
to treat population were used in the post hoc analyses. The
CDRS AUC0-3 was analysed on a log scale so that the estimate
of difference could be presented as a ratio (or equivalent per-
centage). In addition, analyses of untransformed peak CDRS
were performed and repeated measures analyses were of un-
transformed data. Baseline covariates were included on a log
scale where the endpoint was analysed on a log scale; other-
wise baseline covariates were untransformed. All statistical
comparisons were made relative to randomized placebo.
Covariates included baseline placebo treatment and visit (or
visit  time in the mixed model, repeated measures model).
Results
Twenty-five patients were screened and of these, 22
patients met the inclusion/exclusion criteria. They were ran-
domized and included in the intention to treat population
and exposed to placebo (twice) and all three eltoprazine
dosages (2.5, 5, or 7.5 mg) (Fig. 1). During each of the
five dosing visits, patients concomitantly received supra-
threshold dosages of L-DOPA. Two patients taking mirta-
zepin as concomitant medication were randomized even
though they did not meet the eligibility criteria. The data
from these two patients were included in the intention to
treat analysis, but were excluded in the per protocol ana-
lysis. Two patients were given the study medication in the
wrong order per the randomization code. Consequently, 18
patients were included in the per protocol population.
Pharmacokinetics of eltoprazine
A subgroup of 12 patients provided blood samples for
serum measurements of eltoprazine. Figure 2 shows serum
concentrations at 0, 1, 2 and 4 h after administration of
eltoprazine. The maximum concentration (Cmax) was 6.7
(0.2), 13.5 (2.3), and 19.8 (3.5) ng/ml following a single
oral dose of 2.5, 5 and 7.5 mg eltoprazine, respectively.
Likewise the AUC0-4 after 2.5, 5, and 7.5 mg eltoprazine
increased in a dose-proportional manner 18.3, 35.5, and
55.3 ng h/ml, respectively. At all concentrations, the time
to maximum concentration of eltoprazine (Tmax) was be-
tween 2 and 4 h.
Efficacy of eltoprazine
Dyskinesia ratings
The data and results for the primary (CDRS AUC0-3) and
secondary (peak CDRS, RDRS AUC0-3) LID outcome
measures are shown in Tables 2 and 3 (for the intention
to treat population). The individual CDRS data are also
presented in Supplementary Fig. 1. Compared to rando-
mized placebo, there was a significant reduction of LIDs
as measured by CDRS AUC0-3 in the intention to treat
[Table 2; 1.02 (1.49); P = 0.004] and per protocol
[–1.16 (1.61); P = 0.016] populations treated with 5 mg of
eltoprazine. At 2.5 mg [intention to treat: 0.64 (1.62);
P = 0.065; per protocol: 0.65 (1.71); P = 0.084] as well
as 7.5 mg [intention to treat: 0.43 (1.33); P = 0.103; per
protocol: 0.538 (1.375); P = 0.082] eltoprazine tended to
be antidyskinetic on CDRS AUC0-3. Results of the post hoc
analysis supported these findings and provided additional
information on the dose-response relationship. As shown in
Table 4, there was an estimated 15% decrease (P = 0.003)
























Figure 2 Serum concentration of eltoprazine. Eltoprazine
concentration in serum was measured in 12 patients at 2.5 mg, 5 mg
and 7.5 mg. Data are presented as mean  SD.
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in CDRS AUC0-3 at 5 mg of eltoprazine, a 9% decrease
with 7.5 mg (P = 0.083), and a 6% decrease with 2.5 mg
of eltoprazine (P = 0.271). Importantly, the repeated meas-
ures of the change in CDRS, least squares means, at each
time point demonstrate more clearly the dose effect of
eltoprazine and show that the greatest effect appeared to
be in the latter part of the time course, consistent with the
Tmax of eltoprazine (Fig. 3).
With 5 mg eltoprazine, there was a significant reduction
in the maximum LID severity in the 3-h post-dose period
[Table 3; 1.14 (1.59); P = 0.005]. There was a trend to a
reduction in maximum LID severity, post-dose with
2.5 mg [–0.82 (1.89); P = 0.069] as well as 7.5 mg [–0.61
(1.53); P = 0.077]. The post hoc analysis evaluated peak
dose dyskinesia, i.e. that seen at the Tmax peak following
L-DOPA dosing (90 min post L-DOPA). As shown in Table
4 and Fig. 3, the post hoc analysis demonstrated signifi-
cant decreases in peak dose CDRS at both 5 mg
(P = 0.034) and 7.5 mg (P = 0.0427).
Another rating scale for LIDs, RDRS AUC0-3, difference
from placebo was used as a secondary outcome. In ac-
cordance with the data obtained using CDRS, 5 mg of
eltoprazine [–0.15 (0.23); P = 0.003], but not 2.5 mg
[–0.021 (0.188); P = 0.615] or 7.5 mg [–0.026 (0.211);
P = 0.555] of eltoprazine significantly suppressed LIDs
(Table 3). Thus, it has been demonstrated with two inde-
pendent dyskinesia scales, CDRS and RDRS, that eltopra-
zine at 5 mg reduces LIDs.
Parkinsonian ratings
Another primary outcome measure related to the effect of
eltoprazine on the highest observed change in UPDRS-III
score up to 3 h after study medication. The highest
observed change being defined as the difference between
the maximum UPDRS-III score 3 h post-dosing and the
UPDRS-III prior to any study medication. UPDRS-III
scores did not differ between the placebo and eltoprazine
treatments at 2.5, 5 or 7.5 mg [change of 2.52 (9.11),
P = 0.053; 1.17 (6.62), P = 0.156; 0.49 (8.60),
P = 0.375, respectively] (Table 2). No significant differ-
ences were found in UPDRS-III AUC0-3 or maximum
UPDRS-III scores 3 h post-dosing (Table 3). No changes
were found in a diary administered the day before and
after each treatment session (data not shown). Taken to-
gether, these data demonstrate that there is no deterior-
ation of the normal anti-parkinsonian treatment effect of
L-DOPA by eltoprazine co-treatment.
Ratings of mood
Effects of eltoprazine on mood were other secondary out-
comes in the study. HADS-D showed no significant alter-
ations after eltoprazine administration at any of the
studied dosages (Table 3). Likewise, eltoprazine caused
no development of depression over the course of the
study period, as measured by the Montgomery Åsberg
Depression Rating Scale [Screening: intention to treat:
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judgement. However, it was found that HADS-A scores
were significantly higher than placebo after 5 mg eltopra-
zine [0.68 (1.91), P = 0.044], but not for 2.5 mg [0.227
(1.72), P = 0.303] or 7.5 mg [0.364 (1.364), P = 0.282]
(Table 3).
Safety and reported adverse events
There were no discontinuations from the study. There were
no deaths, serious adverse events, or other significant
adverse events. As summarized and detailed in Table 5,
six patients reported treatment-emergent adverse events
(TEAEs) following placebo (Test Session 1), six patients
reported nine TEAEs following placebo (Randomized
Placebo), seven patients reported 10 TEAEs, following
2.5 mg eltoprazine, 12 patients reported 17 TEAEs follow-
ing 5 mg eltoprazine, and 10 patients reported 20 TEAEs
following 7.5 mg eltoprazine. The most frequent TEAEs
following eltoprazine were fatigue, nausea and dizziness.
The only TEAEs that were reported in a treatment group
(i.e. either following 2.5, 5 or 7.5 mg eltoprazine) and not
in the placebo group (either Test Session 1 or Randomized
Placebo) were vaginal haemorrhage (one patient following
2.5 mg), fatigue (three patients following 2.5 mg and two
patients following 5 mg), abdominal pain upper (one pa-
tient following 5 mg), dysgeusia (one patient following
5 mg and one patient following 7.5 mg), and conjunctivitis,
joint dislocation, muscle rigidity, and headache (each in one
patient following 7.5 mg).
The haematology and serum chemistry results at screen-
ing and at the final visit showed that no clinically signifi-
cant changes in mean laboratory parameter values occurred
in the study (data not shown). There were eight protocol
deviations. Most deviations were missed assessments or
visits outside the protocol window. These were considered
to be minor and should not affect the overall outcome of
the study.
Discussion
This study evaluated eltoprazine as a potential novel ther-
apy of LIDs in patients with Parkinson’s disease. This
study was the first exposure of this drug in Parkinson’s
disease and was therefore designed as a single-dose, dose-
finding study to obtain preliminary efficacy and safety
data in Parkinson’s disease patients with LIDs. The
chosen doses are similar to or lower than those given to
patients in other populations. The double-blind, rando-
mized, placebo-controlled crossover design allowed for
intraindividual comparisons of placebo effects as well as
comparisons between the different doses and placebo in an
unbiased manner. Several different rating scales, UPDRS-
III, CDRS and RDRS, were used to address motor symp-
toms and dyskinesias. The CDRS is similar to the
Abnormal Involuntary Movement Scale for dyskinesias
(Guy, 1976), allowing for rating of individual limbs.
CDRS has a high response level and limited ceiling effects
Figure 3 Post hoc analyses of CDRS scores. Mixed model repeated measures analysis of change in CDRS (compared to T = 0) at each time
point over the 3 h session, with data representing least squares means differences from randomized placebo (set as 0 line) with 95% CI (Placebo 1
is baseline placebo, test session 1). Measures are from the intention to treat population (n = 22).
Table 4 Post hoc analyses of AUC0-3 and peak dose dyskinesia scores.
Dose of
eltoprazine
Ratio of least square geometric means CDRS AUC0-3 Difference in least square means peak dose CDRS
(eltoprazine/randomized placebo) (eltoprazine – randomized placebo)
Estimate Lower 95% CI Upper 95% CI P-value Estimate Lower 95% CI Upper 95% CI P-value
2.5 mg 0.94 0.84 1.05 0.2709 –0.8127 –1.8872 0.2517 0.1314
5 mg 0.85 0.77 0.94 0.0027* –1.0186 –1.9601 –0.0770 0.0345*
7.5 mg 0.91 0.81 1.01 0.0827 –1.0533 –2.0707 –0.0358 0.0427*
Left: Ratio of Least Squares Geometric Means (Eltoprazine/Randomized Placebo) in CDRS AUC0-3. Right: Differences of Least Squares Means in peak dose CDRS (90 min post L-
DOPA) from Randomized Placebo. All measures are from the intention to treat population (n = 22). *P5 0.05.
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(Reimer et al., 2004). The difference is that the original
AIMS scale was developed for neuroleptic-induced tardive
dysinesias and includes several ratings of the oral/facial
components of this type of dyskinesias that is omitted in
the CDRS. The CDRS can also be used for simultaneous
dystonia rating if present. The RDRS is functional scale
and complements the CDRS well. As neither the RDRS
nor CDRS assessed patient perception, the patients were
also asked to put scores in a diary the day after the treat-
ment. However, as the main effects of both L-DOPA and
eltoprazine had gone within a few hours, the diary data
turned out to be less useful compared to what they could
become in a study with chronic L-DOPA and eltoprazine
administration.
Table 5 Treatment-emergent adverse events by treatment arm and preferred term.
















2 1 2 4 7
Abdominal pain 1
Dry mouth 1 1
Nausea 1 1 2 4 7
Vomiting 1 1 1
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Rash papular 1 1
Vascular disorders 1
Hypertension 1
Number of adverse events from the intention to treat population (n = 22).
The indicated number for each system organ class represent the number of patients affected. Some patients had more than one AE in a system organ class.
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The major finding of this study was that eltoprazine at
5 mg caused a significant reduction of LIDs measured by
either CDRS or RDRS. The post hoc analysis revealed
that the antidyskinetic effect of eltoprazine was most
prominent, and indicated a dose-response, during the
last hour of the test sessions. In accordance with these
results, the pharmacokinetic analyses demonstrated a
Tmax of eltoprazine between 2 and 4 h post-dosing. In
the present study, eltoprazine and L-DOPA were given at
the same time, but since the Tmax of L-DOPA preceeds that
of eltoprazine by 1 h, it is likely that pretreatment with
eltoprazine prior to L-DOPA would result in a stronger
antidyskinetic effect. It is, thus, probable that the antidys-
kinetic effects of eltoprazine are underestimated in
this study and it will be important to evaluate the anti-
dyskinetic effects of eltoprazine in a chronic study with an
improved pharmacokinetic/pharmacodynamic profile of
eltoprazine dosing.
It has previously been shown in open-label trials that the
5-HT1A receptor agonists buspirone (Kleedorfer et al.,
1991; Bonifati et al., 1994; Politis et al., 2014) and sarizo-
tan (Bara-Jimenez et al., 2005) have antidyskinetic proper-
ties. L-DOPA induces higher striatal synaptic dopamine
concentrations in Parkinson’s disease patients with LIDs
compared with Parkinson’s disease patients without LIDs
(de la Fuente-Fernández et al., 2004) and buspirone prior
to L-DOPA reduced L-DOPA-evoked striatal synaptic dopa-
mine release, particularly in Parkinson’s disease patients
with mild LIDs (Politis et al., 2014). However, since pla-
cebo has a strong effect on LIDs (Goetz et al., 2008), it is
critical to perform placebo-controlled trials with putative
antidyskinetic agents. In a large placebo-controlled trial,
sarizotan failed to convincingly counteract LIDs (Goetz
et al., 2007) and, at higher doses, actually worsened par-
kinsonism. The later effect may partly depend upon its an-
tagonistic actions at dopamine D2-like receptors. No
placebo-controlled trials with buspirone have been
reported.
There is no licensed treatment against LIDs. However,
in addition to targeting the serotonin system, there are
other pharmacological targets, including cholinergic, opio-
dergic and glutamatergic ones that have been reported to
offer benefits for LID (Cenci et al., 2011; Huot et al.,
2013). In particular, antagonism of metabotropic glutam-
ate type 5 receptors (Berg et al., 2011) or NMDA recep-
tors have antidyskinetic properties (Luginger et al., 2000;
Del Dotto et al., 2001; da Silva-Júnior et al., 2005).
Amantadine, a NMDA receptor antagonist (Greenamyre
and O’Brien, 1991), is indeed, recommended for this indi-
cation by the Movement Disorder Society, but many pa-
tients with LIDs do not respond, or show only marginal
response to amantadine (Sawada et al., 2010). There is no
study that has used CDRS to assess L-DOPA-induced dys-
kinesias after acute administration of amantadine so no
direct comparison can be made with our data on eltopra-
zine. However, following 3 weeks of treatment with
amantadine, a 23% reduction of CDRS scores has been
reported (da Silva-Júnior et al., 2005). This reduction is
somewhat higher than observed here after acute eltopra-
zine, but it will be more meaningful to make such com-
parisons when chronic eltoprazine has been investigated.
Based on their pharmacological profile, it is anticipated
that eltoprazine and amantadine inhibit LIDs via distinct
mechanism(s) (Cenci et al., 2011; Huot et al., 2013).
Eltoprazine is exerting antidyskinetic actions by stimulat-
ing 5-HT1A and 5-HT1B autoreceptors and thereby redu-
cing the ‘false’ release of dopamine from serotonin
terminals (Carta et al., 2007; Bezard et al., 2013).
Moreover, 5-HT1B receptors are upregulated in dopamine
D1 receptor containing striatonigral neurons following re-
peated L-DOPA in animal models of parkinsonism (Zhang
et al., 2008). Stimulation of these postsynaptic 5-HT1B
receptors by eltoprazine may counteract LIDs, as has pre-
viously been showed with another 5-HT1B receptor agon-
ist, CP94253 (Carta et al., 2007; Zhang et al., 2008).
Interestingly, a recent study has shown that eltoprazine
and amantadine have additive antidyskinetic actions in
animal models of LIDs (Bezard et al., 2013). Therefore,
in the future clinical development of eltoprazine, in add-
ition to trials aimed at establishing its antidyskinetic effi-
cacy as a standalone treatment, it would be of interest to
examine whether such additive effects can be obtained
also in Parkinson’s disease patients with LIDs treated
with amantadine. It will also be important to examine
whether eltoprazine has antidyskinetic properties in pa-
tients who have not responded to amantadine.
UPDRS-III scores did not differ between the placebo and
eltoprazine treatments demonstrating that there is no de-
terioration of the normal treatment effect of L-DOPA by
eltoprazine co-treatment. To study mood changes, HADS
scores before and after study medication were compared
with placebo at each study visit. A statistical observation
was that HADS-A scores were higher after 5 mg eltopra-
zine, but as fewer patients complained about anxiousness
after eltoprazine than placebo, the clinical significance is
doubtful. The most frequent adverse events reported by
the patients in this study were nausea and dizziness.
Previous studies have shown that adverse events tend to
tolerate out after 2–3 days of dosing and do not emerge
if eltoprazine is dose titrated up from lower doses (de
Koning et al., 1994).
In conclusion, it appears that eltoprazine has beneficial
antidyskinetic effects without altering normal motor re-
sponses to L-DOPA or inducing clinically significant ad-
verse-effects. The most frequent adverse events reported
by the patients in this study were nausea and dizziness,
which is consistent with the adverse events reported in
previous clinical studies with eltoprazine at similar doses.
Moreover, based on preclinical experiments in Parkinson
models and studies with eltoprazine in other disease
conditions, it is anticipated that chronic eltoprazine admin-
istration could provide a more prominent antidyskinetic
effect.
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